Medisafe, an evidenced-based digital therapeutics company providing medication management solutions for patients, is launching the industry’s first end-to-end, holistic patient journey management solution.
The new solution supports patients across the full spectrum of their medication journey from onboarding, to their first prescription fill, through managing complexities across multiple medications, to refilling medications and having them delivered to their door.
The patient journey approach designs programs to reinforce moments of impact for patients. Medisafe has experience with more than 190 reasons for non-adherence and applies real world evidence to build connected medication management programs to influence patients’ behavior on therapy. Working with global pharmaceutical companies, Medisafe delivers digital platforms to engage and support patients throughout their medication journey.
Recently, Medisafe teamed up with Lash Group, a patient support services company that’s part of AmerisourceBergen, to meet end-to-end medication management needs by digitally connecting patients with care support teams.
The Medisafe mobile application provides real-time, personalized interventions using predictive analytics and machine learning, and now through this innovative collaboration, Medisafe will identify “at-risk” patients for Lash Group’s licensed clinicians. This patient journey solution now provides support after therapy is prescribed, but before the first fill. The collaboration also creates visibility into the patient’s approval and shipment status of their medication, while simultaneously providing the opportunity to educate and engage with patients.
Medisafe, in 2018, launched a value-driven partnership model to better align interests with its life sciences partners. Under this data-driven model, Medisafe’s success will be linked directly to an increase in the medication adherence of its users, as measured by their prescription refills. Medisafe will continue to offer a flat SaaS license option in addition to the new variable fee approach.
Medisafe initially launched to biopharma brands in select chronic and specialty therapeutic areas. Pending additional findings from ongoing research and market response to the new offering, Medisafe planned to expand its value-driven model in the next year.
Medisafe partners with pharma and life sciences in the following areas:
- Adherence: Improving dose-level adherence for patients prescribed the brand’s medication.
- Engagement: Delivering personalized content, resources and interventions across the patient journey to keep them engaged and on therapy.
- Insights: Interpreting de-identified cohort-level behavioral trends for Medisafe users relevant to the partnership.
Medisafe has collaborated with Merck KGaA, Darmstadt, Germany. The initiative, which is supporting medication adherence and engagement for patients taking Merck KGaA, Darmstadt, Germany’s cardiometabolic medications has now been launched in Brazil, Mexico and Russia. Together Medisafe and Merck KGaA, Darmstadt, Germany are providing patients access to a version of Medisafe, with targeted content, interventions and additional features to supplement Medisafe’s personalized medication adherence platform.
Medisafe also partnered with Boehringer Ingelheim to deliver an innovative new section within its medication management platform for patients. Medisafe offers access within the overall Medisafe app to a section with educational materials specific to Pradaxa including health literacy videos, relevant health tips and a Pradaxa Savings Card to certain individuals who are taking Pradaxa.
Digital therapeutic and pharmaceutical companies continue to determine how to integrate their resources to collaborate successfully.